<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983226</url>
  </required_header>
  <id_info>
    <org_study_id>SGOG OV5</org_study_id>
    <secondary_id>SGOG OV-05</secondary_id>
    <nct_id>NCT03983226</nct_id>
  </id_info>
  <brief_title>Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)</brief_title>
  <official_title>A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of cytoreductive surgery and Niraparib&#xD;
      maintenance in platinum-sensitive secondary recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory trial is to compare the efficacy of secondary cytoreductive surgery followed&#xD;
      by chemotherapy and Niraparib maintenance, versus chemotherapy alone followed by Niraparib&#xD;
      maintenance in patients with platinum-sensitive secondary recurrent ovarian cancer who never&#xD;
      received secondary cytoreduction when recurrent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month disease non-progression rate</measure>
    <time_frame>up to 12 months after last patient randomized</time_frame>
    <description>12-month non-progression rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 24 months after last patient randomized</time_frame>
    <description>from date of randomization until the date of 3rd relapse/progression or death (whatever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment free intervals</measure>
    <time_frame>Up to 24 months after last patient randomized</time_frame>
    <description>the intervals of the ending date from system anticancer therapy to the starting date of the subsequent anticancer therapy or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately up to 24 months after last patient randomized</time_frame>
    <description>from date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day post-operative complications</measure>
    <time_frame>From the operation until after 30 days</time_frame>
    <description>surgical complications grading criteria will be adopted for evaluating the perioperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>baseline; 6 and 12 months after randomization</time_frame>
    <description>the European Organization for Research and Treatment (EORTC) core quality of life questionnaire (QLQ-C30, version 3.0) The total score (range from 0 to 1,000)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:&#xD;
Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Platinum-based chemotherapy and Niraparib</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Tumor debulking surgery (surgery in recurrent ovarian disease)</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>secondary cytoreduction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...</intervention_name>
    <description>Salvage chemotherapy</description>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>third-line therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib maintenance therapy</description>
    <arm_group_label>No surgery</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>maintenance therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years to ≤ 75 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          -  Patients with platinum-sensitive, secondary relapsed epithelial ovarian, primary&#xD;
             peritoneal, or fallopian tube cancer, which is defined as those with platinum-free&#xD;
             interval of 6 months or more.&#xD;
&#xD;
          -  Front-line or second-line treatment may have included maintenance therapy&#xD;
&#xD;
          -  Never received secondary cytoreductive surgery when recurrence&#xD;
&#xD;
          -  Assessed by the experienced surgeons, complete resection of all recurrent disease is&#xD;
             possible. Single or localized lesions identified by CT, or MRI, or positron emission&#xD;
             tomography/computed tomography (PET/CT). PI and Co-PI reach consensus if extensive&#xD;
             lesions or carcinomatosis.&#xD;
&#xD;
          -  It can be included if single lesion outside the peritoneal cavity can be resected.&#xD;
&#xD;
          -  No more than 3 disease lesions by central-reviewed PET/CT imaging if the participated&#xD;
             center has never participated in any surgical trials on ovarian cancer before.&#xD;
&#xD;
          -  Patients who have given their signed and written informed consent and their consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with borderline tumors as well as non-epithelial tumors.&#xD;
&#xD;
          -  Patients for interval-debulking, or for second-look surgery, or palliative surgery&#xD;
             planned.&#xD;
&#xD;
          -  Patients whom have already undergone secondary cytoreduction for recurrent disease are&#xD;
             excluded.&#xD;
&#xD;
          -  Impossible to assess the resectability. Radiological signs suggesting complete&#xD;
             resection is impossible.&#xD;
&#xD;
          -  Patients who have received more than two previous regimen of chemotherapy (maintenance&#xD;
             is not considered a third regimen).&#xD;
&#xD;
          -  Third relapse or more.&#xD;
&#xD;
          -  Patients with second or other malignancies who have been treated by surgery, if the&#xD;
             treatment might interfere with the treatment of relapsed ovarian cancer or if major&#xD;
             impact on prognosis is expected.&#xD;
&#xD;
          -  Progression during chemotherapy or recurrence within 6 months after second-line&#xD;
             platinum-based therapy&#xD;
&#xD;
          -  Any contradiction not allowing surgery and/or chemotherapy and/or or Niraparib&#xD;
&#xD;
          -  Accompanied by hypoxia serious chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Uncontrolled hypertension, cerebrovascular accident/ Stroke, myocardial infarct,&#xD;
             unstable angina, untreated thrombosis, chronic congestive heart failure, or serious&#xD;
             arrhythmia in need of medicine.&#xD;
&#xD;
          -  Severe hepatitis, history of liver disease, nephrotic syndrome, renal insufficiency&#xD;
&#xD;
          -  Active ulcer history, abdominal wall fistula, perforation of gastrointestinal tract,&#xD;
             or Intra-abdominal abscess, or simultaneously apply treatment/prevent ulcers therapy.&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Uncontrolled epilepsy need long-term antiepileptic treatment.&#xD;
&#xD;
          -  Any medication induced considerable risk of surgery, e.g. estimated bleeding due to&#xD;
             oral anticoagulating agents.&#xD;
&#xD;
          -  ≥3 grade anemia, neutropenia or thrombocytopenia due to chemotherapy, and lasted for&#xD;
             more than 4 weeks&#xD;
&#xD;
          -  Patients with a known hypersensitivity to Niraparib or any of the excipients of the&#xD;
             product.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingyan Shi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongyu Zang, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Jiang, M.D.</last_name>
    <phone>+862164041990</phone>
    <email>jiang.rong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, R.N.</last_name>
    <phone>+862164041990</phone>
    <email>yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Jiang, MD</last_name>
      <phone>+862164041990</phone>
      <email>jiang.rong@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuting Luan, RN</last_name>
      <phone>+862164041990</phone>
      <email>yutingluan@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanling Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wen Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Bao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reurrent Ovarian Cancer</keyword>
  <keyword>Secondary Cytoreductive Surgery</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Niraparib maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Niraparib</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

